Investor Moves
| Investor | Portfolio Value | Portfolio Change | Position Change | Avg Buy Price | Current Price |
|---|---|---|---|---|---|
Ken GriffinCitadel Advisors $-374.6K ExitQ4 2025 $375k -- -- | |||||
Ken GriffinCitadel Advisors $-374.6K ExitQ4 2025 $375k -- -- | |||||
Ken GriffinCitadel Advisors $-266.7K ExitQ2 2024 $267k -- -- | |||||
News
newsfilecorp.comRed Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in Francenewsfilecorp.comJun 8
newsfilecorp.comRed Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for Study Probing Preclinical Alzheimer's Markersnewsfilecorp.comJun 4
newsfilecorp.comRed Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidatenewsfilecorp.comMay 25
newsfilecorp.comRed Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechanism Researchnewsfilecorp.comMay 14
newsfilecorp.comRed Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutionsnewsfilecorp.comMay 7